Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABBNY vs EMR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EMR Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

EMR Overall Winner 6-Pillar Tally: ABBNY 0 – 6 EMR Matrix Metrics: ABBNY 1 – 9 EMR

As of Nov 16, 2026, Emerson Electric Co. (EMR) is the stronger overall head-to-head candidate over ABBNY (ABBNY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABBNY carries a Unified Composite Score of 55.7/100 (HOLD) at $83.75 (N/M Forward P/E, N/A operating margin), whereas EMR carries 51.2/100 (HOLD) at $161.06 (22.9x Forward P/E, 24.8% operating margin).

  • Composite vs. Pillar Nuance: While ABBNY currently prints a higher short-term Unified Composite Score (55.7/100 HOLD vs. EMR 51.2/100 HOLD), EMR captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (24.8% vs. N/A operating margin) and revenue trajectory (+7.1% vs. N/A YoY).
  • Technical & Structure Timing Caution: ABBNY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.1); meanwhile EMR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABBNY vs EMR
ABBNY US Equity
ABBNY
Institutional Equity
$83.75
+0.01% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.81β · 41% Vol
Unified Composite Score
55.7 / 100 HOLD
Tech 83.0 Fund 56.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.8%), weak momentum, RSI 41
RSI-14: 41.1 · SMA20: $85.16 · SMA50: $91.91
EMR NYSE Head-to-Head Winner
Emerson Electric Co.
Electronic & Other Electrical Equipment (No Computer Equip)
$161.06
-3.2% 1D
Market Cap $91.6B
TTM Revenue $19.0B
Forward P/E 22.9x
Beta / 30D Vol 1.45β · 34% Vol
Unified Composite Score
51.2 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 59.0 Mom 45.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.2 · SMA20: $165.18 · SMA50: $159.74

6-Pillar Scorecard Institutional Category Breakdown (ABBNY 0 – 6 EMR)

Columns: Metric · ABBNY · EMR
1. Valuation Multiples EMR
Forward P/E N/M 22.9x
Trailing P/E N/M 34.9x
PEG Ratio N/M 2.02x
EV / Revenue N/M 5.4x
2. Growth & Scale EMR
Revenue Growth (YoY) N/A +7.1%
Earnings Growth (YoY) N/A +23.8%
TTM Revenue (USD) N/A $19.0B
Market Cap N/A $91.6B
3. Profitability & Quality EMR
Gross Margin N/A 52.7%
Operating Margin N/A 24.8%
Net Profit Margin N/A 14.2%
Return on Equity (ROE) N/A 13.1%
4. Balance Sheet & Cash Flow EMR
Cash Generation (TTM) N/A $3.54B
Cash Flow Margin N/A 18.6%
Net Cash / Leverage N/A ROE $11.1B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) 1.33%
5. Options & Positioning EMR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 46.6% (6th %ile)
Put/Call OI Skew N/A 0.40x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat EMR
OpEx & R&D Intensity N/A 27.9% of Rev ($5.30B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator Specialty Industrial Machinery Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABBNY (1) vs EMR (9)
Institutional Metric ABBNY EMR Criterion Row Edge
Market Capitalization
Scale
N/A $91.6B Larger Scale EMR
Trailing P/E Ratio
Valuation
N/M 34.9x Lower Multiple EMR
Forward P/E Ratio
Valuation
N/M 22.9x Lower Multiple EMR
Revenue Growth (YoY)
Growth
N/A +7.1% Higher Growth EMR
Operating Margin (TTM)
Profitability
N/A 24.8% Higher Margin EMR
Net Profit Margin
Profitability
N/A 14.2% Higher Margin EMR
Return on Equity (ROE)
Capital Efficiency
N/A 13.1% Higher ROE EMR
52-Week Range Position
Momentum
38% ($67–$110) 78% ($123–$172) Stronger Trend EMR
Beta / 30D Volatility
Risk Regime
1.81β · 41% Vol 1.45β · 34% Vol Lower Realized Risk EMR
Unified Institutional Score
Composite Signal
55.7 / 100 (HOLD) 51.2 / 100 (HOLD) Higher Composite ABBNY
Trailing 12M Revenue (USD)
Operating Scale
N/A $19.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 52.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.02x PEG · 5.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $3.54B ($11.1B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EMR +12.25 pp
ABBNY: -9.64% · EMR: +2.61%
3M Horizon EMR +20.67 pp
ABBNY: -18.0% · EMR: +2.67%
6M Horizon EMR +44.45 pp
ABBNY: -19.4% · EMR: +25.05%
1Y Horizon EMR +10.69 pp
ABBNY: +18.83% · EMR: +29.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABBNY vs EMR. Trailing 12-month operating profitability (ABBNY N/A vs EMR 24.8%) and valuation multiples (ABBNY N/M vs EMR 22.9x Forward P/E) are benchmarked directly in Pillar 4 below.

ABBNY ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
EMR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19.0B
Gross Margin52.7%
Op. Margin24.8%
ROE / Fwd P/E13.1% · 22.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABBNY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABBNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EMR CONSOLIDATION
68d in phase · OBV DISTRIBUTION
Current IV 46.6%
IV Percentile 6th %ile
Put/Call OI Skew 0.40x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABBNY Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EMR Moat Profile Scale & Operating Efficiency Moat
Specialty Industrial Machinery Operator
Competes within the Specialty Industrial Machinery value chain with $91.6B market capitalization and 24.8% operating margin.
OpEx & R&D Reinvestment 27.9% of Rev ($5.30B)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (15 partners):
Taiwan Semiconductor Manufacturing Company Amkor Technology ASE Technology Holding Cadence Design Systems

Investor FAQ ABBNY vs EMR Key Questions & Quantitative Answers

As of Nov 16, 2026, Emerson Electric Co. (EMR) is the stronger overall head-to-head candidate over ABBNY (ABBNY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABBNY carries a Unified Composite Score of 55.7/100 (HOLD) at $83.75 (N/M Forward P/E, N/A operating margin), whereas EMR carries 51.2/100 (HOLD) at $161.06 (22.9x Forward P/E, 24.8% operating margin). Composite vs. Pillar Nuance: While ABBNY currently prints a higher short-term Unified Composite Score (55.7/100 HOLD vs. EMR 51.2/100 HOLD), EMR captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (24.8% vs. N/A operating margin) and revenue trajectory (+7.1% vs. N/A YoY). Technical & Structure Timing Caution: ABBNY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.1); meanwhile EMR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 46.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EMR leads the Growth & Scale pillar: ABBNY posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with EMR at +7.1% YoY revenue growth and +23.8% YoY earnings growth on $19.0B TTM revenue (52.7% gross margin, 24.8% operating margin). On trailing 12-month operating scale, ABBNY generates N/A in USD-normalized revenue versus $19.0B for EMR. In operating R&D and SG&A reinvestment, ABBNY deploys N/A (0 90-day corporate R&D disclosures) versus 27.9% of Rev ($5.30B) (0 disclosures) for EMR.

EMR screens cheaper on headline valuation multiples. ABBNY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas EMR trades at 22.9x Forward P/E, 34.9x Trailing P/E, 2.02x PEG, and 5.4x EV/Revenue (18.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABBNY (N/A ROE) versus EMR (13.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ABBNY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.81β · 41% Vol realized risk). By comparison, EMR carries 46.6% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.40x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.45β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.